VNDA:NASDAQVanda Pharmaceuticals Inc. Analysis
Data as of 2026-09-02 - not real-time
$5.42
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At $5.42, Vanda Pharmaceuticals Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. The last 30 days have lost 1.1%. RSI sits at 51.7, which reads as neutral, and MACD momentum is bullish. Recent trading has carved out support near $4.45 and resistance around $5.59.
Multiples put this in undervalued territory: 27.1 times earnings against the sector's 30.6. Sell-side targets cluster 124.9% above the current quote. Revenue is contracting at 3.9% on a -127.4% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 39.5%, a beta of 0.78 and a maximum drawdown of 48.4%, position sizing matters here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Multiples put this in undervalued territory: 27.1 times earnings against the sector's 30.6. Sell-side targets cluster 124.9% above the current quote. Revenue is contracting at 3.9% on a -127.4% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 39.5%, a beta of 0.78 and a maximum drawdown of 48.4%, position sizing matters here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top Market Events
Updated Aug 5, 2026 0 - Fanapt® Q2 2026 net product sales increased 23% to $36.Fanapt® Q2 2026 net product sales increased 23% to $36.Updated Jul 29, 2026 0 Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 6.56
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- P/E of 27.1 versus sector average of 30.6
- Trading below the 200-day average of 6.56
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 27.1 versus sector average of 30.6
- Negative profit margin of -127.4%
- Analyst targets imply +124.9% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth-3.90%
Profit Margin-127.41%
P/E Ratio27.1
ROE-77.81%
ROA-22.38%
Debt/Equity10.37
P/B Ratio1.2
Op. Cash Flow$-142331008
Free Cash Flow$-86717752
Industry P/E30.6
Technical Analysis
TrendBearish
RSI51.7
Support$4.45
Resistance$5.59
MA 20$5.26
MA 50$5.54
MA 200$6.56
MACDBullish
VolumeDecreasing
Fear & Greed Index91.43
Valuation
Target Price$12.19
Upside/Downside124.86%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.78
Volatility39.47%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.